Aerosol amphotericin B for prevention of invasive pulmonary aspergillosis.
The pharmacokinetics and applicability of aerosol amphotericin B administrations were studied in 40 neutropenic patients and 4 healthy volunteers. Particle size was measured and pulmonary deposition was demonstrated by radioisotope studies. Inhalations were easy to administer and were well tolerated, with minimal systemic absorption of the drug.
Beyer
J
J
Abteilung Innere Medizin mit Schwerpunkt Hämatologie und Onkologie, Universitätsklinikum Rudolf Virchow, Freien Universität Berlin, Federal Republic of Germany.
Barzen
G
G
Risse
G
G
Weyer
C
C
Miksits
K
K
Dullenkopf
K
K
Huhn
D
D
Siegert
W
W
D000280:Administration, Inhalation; D000284:Administration, Oral; D000336:Aerosols; D000666:Amphotericin B / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001228:Aspergillosis / Q000517:prevention & control*; D006801:Humans; D008172:Lung Diseases, Fungal / Q000517:prevention & control*; D009503:Neutropenia / Q000188:drug therapy; D010316:Particle Size; D014018:Tissue Distribution
D000336:Aerosols; D000666:Amphotericin B